Cornerstone Therapeutics Adjourns Special Meeting of Stockholders
January 31, 2014 18:56 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Jan 31, 2014) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornerstone") today announced that the special meeting of its stockholders scheduled to take place today has...
Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of Cystic Fibrosis Patients With Pseudomonas Aeruginosa
November 20, 2013 08:02 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Nov 20, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today the launch of BETHKIS® (Tobramycin Inhalation Solution), a nebulized therapy indicated for...
Cornerstone Therapeutics Reports Third Quarter 2013 Financial Results
November 07, 2013 07:01 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Nov 7, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX)
Record quarterly net revenue of $53.7 million, up 43% compared to the third...
Cornerstone Therapeutics to Host Third Quarter 2013 Conference Call
October 31, 2013 17:01 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Oct 31, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that it will host a conference call at 8:30 a.m. ET on Thursday, November 7, 2013, to discuss...
Cornerstone Therapeutics Announces Events to Be Held at the 2013 North American Cystic Fibrosis Conference
October 17, 2013 09:00 ET
|
Cornerstone Therapeutics
SALT LAKE CITY, UT--(Marketwired - Oct 17, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) will exhibit at the North American Cystic Fibrosis Conference (NACFC), Oct. 17-19 at the Salt...
Chiesi Farmaceutici and Cornerstone Therapeutics Announce Agreement for a Merger Transaction in Which Chiesi Will Acquire 100 Percent Ownership of Cornerstone for $9.50 per Share in Cash
September 16, 2013 07:30 ET
|
Cornerstone Therapeutics
PARMA, ITALY and CARY, NC--(Marketwired - Sep 16, 2013) - Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading European pharmaceutical company, and Cornerstone Therapeutics Inc. (NASDAQ: CRTX)...
Cornerstone Therapeutics Reports Second Quarter 2013 Financial Results
August 06, 2013 07:02 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Aug 6, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX)
Record net revenue for the second consecutive quarter, up 88% compared to the...
Cornerstone Therapeutics to Host Second Quarter 2013 Conference Call
July 30, 2013 17:01 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Jul 30, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced that it will host a conference call at 8:30 a.m. ET on Tuesday, August 6, 2013, to discuss its...
Cornerstone Therapeutics Initiates PERTZYE(R) (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis
July 29, 2013 18:18 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Jul 29, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for the treatment of...
Cornerstone Therapeutics Sues to Enforce Its CARDENE(R) I.V. Patents
July 24, 2013 17:16 ET
|
Cornerstone Therapeutics
CARY, NC--(Marketwired - Jul 24, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) ("Cornerstone" or "the Company") filed a Complaint earlier today in the United States District Court for the...